1. Apoptosis Metabolic Enzyme/Protease Cell Cycle/DNA Damage NF-κB MAPK/ERK Pathway Immunology/Inflammation PI3K/Akt/mTOR
  2. Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt
  3. Tauroursodeoxycholate dihydrate

Tauroursodeoxycholate dihydrate  (Synonyms: Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate)

Cat. No.: HY-19696B Purity: 99.96%
Handling Instructions Technical Support

Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease.

For research use only. We do not sell to patients.

Tauroursodeoxycholate dihydrate Chemical Structure

Tauroursodeoxycholate dihydrate Chemical Structure

CAS No. : 117609-50-4

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 82 publication(s) in Google Scholar

Other Forms of Tauroursodeoxycholate dihydrate:

Top Publications Citing Use of Products

79 Publications Citing Use of MCE Tauroursodeoxycholate dihydrate

WB

    Tauroursodeoxycholate dihydrate purchased from MedChemExpress. Usage Cited in: BMC Mol Cell Biol. 2023 Mar 3;24(1):7.  [Abstract]

    Tauroursodeoxycholate (TUDCA; 2 mM) not only suppresses the expression of RPL11-induced ERS-related proteins but also markedly mitigates the expression of LC3-II and BECN1 and increases the expression of p62 in RPL11-overexpressing NSCLC cells.

    Tauroursodeoxycholate dihydrate purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 May 24;154:278-292.  [Abstract]

    TUDCA treatment inhibits the secretion of active IL-1β into cell culture media by Acetaminophen (APAP).

    Tauroursodeoxycholate dihydrate purchased from MedChemExpress. Usage Cited in: Fundam Clin Pharmacol. 2018 Aug;32(4):363-377.  [Abstract]

    Effect of TUDCA and Fluoxetine on chronic unpredictable stress (CUS)-induced increase in Iba-1 protein expression in mice hippocampus and prefrontal cortex.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease[1][2][3][4][5][6][7][8][9][10].

    IC50 & Target[1][2][3][4][5][6][7][8][9][10]

    Human Endogenous Metabolite

     

    Caspase-3

     

    Caspase-7

     

    IRE1α

     

    In Vitro

    Tauroursodeoxycholate (5 μM) dihydrate induces a sustained increase of [Ca2+]i in isolated hepatocytes[1].
    Tauroursodeoxycholate (50 μM; 4 h) dihydrate reduces Glycochenodeoxycholic acid (HY-N2334)-induced apoptosis in primary human hepatocytes, as indicated by decreased oligonucleosomal DNA cleavage[4].
    Tauroursodeoxycholate (50-500 μM) dihydrate inhibits Clostridioides difficile toxin-induced caspase-3/7 activation in Caco-2 and HCT116 cells[5].
    Tauroursodeoxycholate (500 mM; 6-hour co-stimulation) dihydrate attenuates the increased expression of inflammation-related factors and innate immunity components in Caco-2 cells co-stimulated with Palmitic acid (HY-N0830) and LPS[9].
    Tauroursodeoxycholate (0-100 μM; 24 h) dihydrate dose-dependently suppresses the expression of inflammatory factors and the activity of the IRE1α/TRAF2/NF-κB pathway in Kupffer cells activated by LPS [10].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Tauroursodeoxycholate (500 mg/kg; s.c.; every 3 days or daily) dihydrate preserves photoreceptor structure and function, reduces apoptosis in retinal degeneration models (rd1, rd10 mice, s334ter-3 rats, P23H-3 rats), and prevents lens epithelial cell death and cataract formation in galactosemic rats[2].
    Tauroursodeoxycholate (250 mg/kg; i.p.; twice a day; 8 weeks) dihydrate attenuates renal tubular injury in a mouse model of type 2 diabetes[7].
    Tauroursodeoxycholate (50 mg/kg; i.p.; once a day; 3 days) dihydrate prevents MPTP (HY-W114750) -induced JNK phosphorylation, impairs ROS production, activates Akt signaling, and protects against MPTP-induced dopaminergic degeneration in C57BL/6 GSTP null mice[8].
    Tauroursodeoxycholate (1000 mg/kg; p.o.; once daily; 4 weeks) dihydrate attenuates HFD-induced hepatic steatosis, inflammation, obesity, insulin resistance, improves intestinal barrier function, decreases intestinal fat transport, and modulates gut microbiota composition in C57BL/6J mice[9].
    Tauroursodeoxycholate (400 mg/kg; i.p.; once per day; 3 days) dihydrate alleviates hepatic I/R injury, reduces levels of liver function markers, hepatocyte apoptosis, proinflammatory factors, and suppresses the function of Kupffer cells by down-regulating the IRE1α/TRAF2/NF-κB pathway in male Balb/c mice[10].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male db/db (C57BLKS/J-LepRdb/LepRdb) mice (6 weeks old) with type 2 diabetes; age-matched lean non-diabetic littermates db/m (C57BLKS/J-LepRdb/+) mice as normal control[7]
    Dosage: 250 mg/kg
    Administration: Intraperitoneal injection, twice a day, 8 weeks
    Result: Significantly reduced blood glucose and albuminuria.
    Ameliorated renal histopathological changes including mesangial cell proliferation, mesangial matrix expansion, and collagen deposition.
    Decreased expression of ER stress markers (GRP78, CHOP) and ER stress-associated apoptotic markers (cleaved caspase12, cleaved caspase3).
    Reduced number of TUNEL-positive tubular cells.
    Molecular Weight

    535.73

    Formula

    C26H49NO8S

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    C[C@H](CCC(NCCS(=O)(O)=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C.O.O

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 83.33 mg/mL (155.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.8666 mL 9.3331 mL 18.6661 mL
    5 mM 0.3733 mL 1.8666 mL 3.7332 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.96%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.8666 mL 9.3331 mL 18.6661 mL 46.6653 mL
    5 mM 0.3733 mL 1.8666 mL 3.7332 mL 9.3331 mL
    10 mM 0.1867 mL 0.9333 mL 1.8666 mL 4.6665 mL
    15 mM 0.1244 mL 0.6222 mL 1.2444 mL 3.1110 mL
    20 mM 0.0933 mL 0.4667 mL 0.9333 mL 2.3333 mL
    25 mM 0.0747 mL 0.3733 mL 0.7466 mL 1.8666 mL
    30 mM 0.0622 mL 0.3111 mL 0.6222 mL 1.5555 mL
    40 mM 0.0467 mL 0.2333 mL 0.4667 mL 1.1666 mL
    50 mM 0.0373 mL 0.1867 mL 0.3733 mL 0.9333 mL
    60 mM 0.0311 mL 0.1556 mL 0.3111 mL 0.7778 mL
    80 mM 0.0233 mL 0.1167 mL 0.2333 mL 0.5833 mL
    100 mM 0.0187 mL 0.0933 mL 0.1867 mL 0.4667 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Tauroursodeoxycholate dihydrate
    Cat. No.:
    HY-19696B
    Quantity:
    MCE Japan Authorized Agent: